Condition: Colorectal Cancer · Sponsor: AbbVie
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621 | Huntsville, Alabama, United States | Recruiting |
| Providence Medical Foundation - Fullerton /ID# 274207 | Fullerton, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center /ID# 274550 | Los Angeles, California, United States | Recruiting |
| Mayo Clinic Hospital Jacksonville /ID# 274472 | Jacksonville, Florida, United States | Recruiting |
| Moffitt Cancer Center /ID# 274372 | Tampa, Florida, United States | Recruiting |
| University of Chicago Medical Center /ID# 274742 | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins Hospital /ID# 275645 | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital /ID# 273608 | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Health System - Ann Arbor /ID# 273511 | Ann Arbor, Michigan, United States | Recruiting |
| Scri Minnesota Oncology Hematology, P.A. /ID# 275149 | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic-Rochester /ID# 273508 | Rochester, Minnesota, United States | Recruiting |
| Northwell Health Center for Advanced Medicine. /ID# 275331 | Lake Success, New York, United States | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07023289